Comparative Pharmacology
Head-to-head clinical analysis: ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL versus VAGIFEM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL versus VAGIFEM.
ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL vs VAGIFEM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination hormonal contraceptive: ethynodiol diacetate is a progestin that suppresses gonadotropin secretion (LH and FSH) via negative feedback on the hypothalamic-pituitary axis, inhibiting ovulation; ethinyl estradiol is an estrogen that stabilizes the endometrium and increases cervical mucus viscosity, impeding sperm penetration.
Estradiol is a form of estrogen that binds to estrogen receptors, activating gene transcription and leading to various physiological effects. It replaces endogenous estrogen in postmenopausal women, alleviating symptoms of vaginal atrophy.
1 tablet (1 mg ethynodiol diacetate / 35 mcg ethinyl estradiol) orally once daily for 21 days, followed by 7 placebo days.
One vaginal tablet (10 mcg estradiol) inserted daily for 2 weeks, then maintenance of one tablet twice weekly.
None Documented
None Documented
Ethynodiol diacetate: 12-14 hours; ethinyl estradiol: 13-27 hours (mean ~17 hours). Steady-state achieved after 3-4 days.
The terminal elimination half-life of estradiol is approximately 2-3 hours. Due to enterohepatic recirculation, the effective half-life may be longer, and daily dosing maintains steady-state concentrations.
Renal (approximately 40% as metabolites), fecal (approximately 60% as metabolites). Ethynodiol diacetate is extensively metabolized; less than 1% excreted unchanged.
Vagifem (estradiol) undergoes hepatic metabolism and renal excretion. Approximately 60-80% of a dose is excreted in urine as glucuronide and sulfate conjugates, with about 10-15% excreted in feces via biliary elimination. Unchanged estradiol is minimally excreted.
Category D/X
Category C
Estrogen
Estrogen